| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA731: Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) Vericiguat was considered not suitable for AWMSG reassessment by the AWMSG Scrutiny Panel at their meeting on 07/08/2025. |
|
Medicine details |
|
| Medicine name | vericiguat (Verquvo®) |
| Formulation | 2.5 mg, 5 mg, 10 mg film-coated tablet |
| Reference number | 3365 |
| Indication | Treatment of symptomatic chronic heart failure in adults with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Scrutiny Panel meeting date | 07/08/2025 |
| Date of issue | 24/06/2021 |
| NICE guidance | |
| Further information Vericiguat was considered not suitable for AWMSG re-assessment by the AWMSG Scrutiny Panel at their meeting on 07/08/2025. Unmet clinical need was not established. As the company were not able to submit to AWMSG, a full HTA assessment would have been required using evidence in the public domain. However, there is a paucity of clinical data due to a change in clinical pathway on which to undertake a meaningful assessment by AWMSG. |
|